ArticleQuantitative imaging in medicine and surgery2021
Dual-energy CT quantitative parameters for the differentiation of benign from malignant lesions and the prediction of histopathological and molecular subtypes in breast cancer.
Article in Quantitative imaging in medicine and surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 42 citations in OpenAlex.
- Noninvasive stratification of HER2 status in breast cancer using multiparametric DECT: a prospective cohort study.International journal of surgery (London, England) · 2026Article
- Pretreatment dual-energy CT versus diffusion-weighted imaging for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer.BMC medical imaging · 2026Article
- Spectral Precision: The Added Value of Dual-Energy CT for Axillary Lymph Node Characterization in Breast Cancer.Cancers · 2026Article
- Differentiation of bilateral BI-RADS 4 breast lesions with one benign and one malignant finding using dual-layer detector spectral CT: a case report.Frontiers in oncology · 2026Article
- Machine learning model incorporating spectral CT quantitative parameters and clinical characteristics for differentiation of benign and malignant thyroid nodules.BMC medical imaging · 2025Article
- Article
- Predict status of axillary lymph node after neoadjuvant chemotherapy with dual-energy CT in breast cancer.BMC medical imaging · 2025Article
- Prediction models for differentiating benign from malignant liver lesions based on multiparametric dual-energy non-contrast CT.European radiology · 2025Article
- Dual-layer detector spectral computed tomography quantitative parameters for predicting pathological complete remission after neoadjuvant treatment of breast cancer.Quantitative imaging in medicine and surgery · 2025Article
- A prediction model based on dual-layer spectral detector computed tomography for distinguishing nonluminal from luminal invasive breast cancer.Quantitative imaging in medicine and surgery · 2024Article
- Value of spectral parameters in the differential diagnosis of benign and malignant breast nodules in non-enhanced chest CT.Quantitative imaging in medicine and surgery · 2024Article
- Differentiating between benign and malignant breast lesions using dual-energy CT-based model: development and validation.Insights into imaging · 2024Article
- What to Expect (and What Not) from Dual-Energy CT Imaging Now and in the Future?Journal of imaging · 2024Review
- Advancing Differentiation of Hepatic Metastases in Malignant Melanoma through Dual-Energy Computed Tomography Rho/Z Maps.Diagnostics (Basel, Switzerland) · 2024Article
- The diagnostic performance of dual-energy CT imaging in cervical lymph node metastasis of papillary thyroid cancer: a meta-analysis.Frontiers in medicine · 2024Review
- Diagnostic Value of Carotid Plaque Assessment with AIS Based on Quantitative Parameters of Dual-Layer Detector Spectral CT.International journal of general medicine · 2024Article
- Dual-Energy CT in Breast Cancer: Current Applications and Future Outlooks.Precision radiation oncology · 2023Review
- Value of spectral computed tomography-derived quantitative parameters based on full volume analysis in the diagnosis of benign/malignant and pathological subtypes of solitary pulmonary nodules.Quantitative imaging in medicine and surgery · 2023Article
- Dual-energy CT for the detection of skull base invasion in nasopharyngeal carcinoma: comparison of simulated single-energy CT and MRI.Insights into imaging · 2023Article
- Evaluation of optimal monoenergetic images acquired by dual-energy CT in the diagnosis of T staging of thoracic esophageal cancer.Insights into imaging · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDual-energy computed tomography (DECT) is widely used to characterize and differentiate tumors. However, data regarding its diagnostic performance for the characterization of breast tumors are limited. In this study, we assessed the diagnostic performance of quantitative parameters derived from DECT in differentiating benign from malignant lesions and predicting histopathological and molecular subtypes in patients with breast cancer.
methodsDual-phase contrast-enhanced DECT of the thorax was performed on participants with breast tumors. Conventional CT attenuation and DECT quantitative parameters, including normalized iodine concentration (NIC), the slope of the spectral Hounsfield unit curve (λ
resultsThis study included 130 participants with 161 breast lesions (44 benign and 117 malignant). In the arterial and venous phase, NICs, λ
conclusionsDual-energy CT quantitative parameters are a feasible and valuable noninvasive means of differentiating between benign and malignant lesions, and predicting histopathological and molecular subtypes in patients with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.